Experienced in Atypical Teratoid Rhabdoid Tumor (ATRT)

Dr. Anne M. Traynor

Oncology
4910 Groton Ln, 
Madison, WI 
Experienced in Atypical Teratoid Rhabdoid Tumor (ATRT)
4910 Groton Ln, 
Madison, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anne Traynor is an Oncologist in Madison, Wisconsin. Dr. Traynor is rated as an Experienced provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Tubal Ligation.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WI
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

4910 Groton Ln, Madison, WI 53711

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Phase Ib Study of Brigatinib Plus Bevacizumab in Patients With ALK-Rearranged Non-Small Cell Lung Cancer (NSCLC) Who Have Previously Progressed on Prior ALK-Directed Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Brigatinib
Study Phase: Phase 1
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 9 Less Clinical Trials

65 Total Publications

Examining the Instructional Sensitivity of Constructed-Response Achievement Test Item Scores.
Examining the Instructional Sensitivity of Constructed-Response Achievement Test Item Scores.
Journal: Educational and psychological measurement
Published: February 03, 2025
Similar Doctors
Distinguished in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Henry I. Robins
Oncology | Radiation Oncology
Distinguished in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Henry I. Robins
Oncology | Radiation Oncology
7887 Almor Dr, 
Verona, WI 
 (7.8 miles away)
608-263-1416
Languages Spoken:
English
See accepted insurances

Henry Robins is an Oncologist and a Radiation Oncologist in Verona, Wisconsin. Dr. Robins is rated as a Distinguished provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Glioblastoma, and Neuroepithelioma.

Distinguished in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Ankush Bhatia
Neurology | Oncology | Pediatric Neurology
Distinguished in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Ankush Bhatia
Neurology | Oncology | Pediatric Neurology

University Of Wisconsin Medical Foundation Inc

600 Highland Ave, 
Madison, WI 
 (1.9 miles away)
608-263-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ankush Bhatia is a Neurologist and an Oncologist in Madison, Wisconsin. Dr. Bhatia is rated as a Distinguished provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Brain Tumor, Glioma, Astrocytoma, and Glioblastoma. Dr. Bhatia is currently accepting new patients.

Advanced in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Alaeddin A. Maeza
Hematology Oncology | Hematology | Oncology
Advanced in Atypical Teratoid Rhabdoid Tumor (ATRT)
Dr. Alaeddin A. Maeza
Hematology Oncology | Hematology | Oncology

Swedishamerican Hospital

3505 N Bell School Rd, 
Rockford, IL 
 (57.4 miles away)
779-696-0300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alaeddin Maeza is a Hematologist Oncology specialist and a Hematologist in Rockford, Illinois. Dr. Maeza is rated as an Advanced provider by MediFind in the treatment of Atypical Teratoid Rhabdoid Tumor (ATRT). His top areas of expertise are Squamous Cell Skin Carcinoma, Paget Disease of the Breast, Oral Squamous Cell Carcinoma, Lung Cancer, and Shoulder Arthroscopy. Dr. Maeza is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Traynor's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile